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Uterine cervical neoplasmsBackground: Cervical intraepithelial neoplasia (CIN) stage 2–3 is a premalignant lesion that can progress to cervical
cancer in 10–20 years if untreated. Objectives: To conduct systematic reviews of randomized and nonrandomized
studies for effects of cryotherapy, loop electrosurgical excision procedure (LEEP), and cold knife conization (CKC)
as treatment for CIN 2–3. Search strategy:Medline, Embase, and other databases were searched to February 2012
for beneﬁts, and to July 2012 for harms. Additionally, experts were contacted. Keywords for CIN, cervical cancer,
and the treatments were used. Selection criteria: Studies of nonpregnant women 18 years or older not previously
treated for CINwere included.Data collection and analysis: Two investigators independently screenedand collected
data. Relative risks and proportions were calculated and evidence assessed using GRADE (Grading of Recommen-
dations Assessment, Development and Evaluation).Main results: Recurrence rate was 5.3% 12 months after cryo-
therapy or LEEP, and 1.4% after CKC. There seemed to be little or no differences in frequency of complications after
LEEP or cryotherapy, but they occurredmore often after CKC. Evidence suggests premature delivery is most com-
monwith CKC, but it also occurs after LEEP and cryotherapy. Conclusions:Despite a comprehensive search, there is
very low quality evidence and often no evidence for important outcomes, including reproductive outcomes and
complications. Studies assessing these outcomes are needed.
© 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
Cervical intraepithelial neoplasia (CIN) is a premalignant lesion that
can be conﬁrmed histologically from a biopsy sample and divided into
three stages (1, 2, and 3). It is estimated that, in 70% of affected
women, CIN 2–3 can persist or progress to cervical cancer after
10–20 years [1,2]. For this reason, treatment is typically provided to
womenwith histologically conﬁrmed CIN 2–3. There are three principle
treatment options available in low- and middle-income countries:pidemiology and Biostatistics,
rsity, 1280 Main Street West,
931; fax: +1 905 522 9507.
J. Schünemann).
and Obstetrics. Published by Elsevier Icryotherapy, loop electrosurgical excision procedure (LEEP; including
large loop excision of the transformation zone or cone biopsy with
loop excision), and cold knife conization (CKC).
In 2012, WHO committed to updating recommendations for the
treatment of precancerous cervical lesions. Although a body of data
from randomized controlled trials (RCTs) comparing the effects of
these treatments would provide the best evidence about the beneﬁts
and harms to support these recommendations, a recently updated and
comprehensive Cochrane systematic review of all surgical options con-
ﬁrmed that there are few RCTs available [3]. These RCTs also do not in-
clude data for important patient outcomes, such as adverse effects on
maternal and fetal outcomes. However, nonrandomized studies could
provide complementary information, particularly for adverse effects
or complications [4].reland Ltd. All rights reserved.
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conducted of the best available evidence for the beneﬁts and harms of
the three treatment options for histologically conﬁrmed CIN 2–3. It in-
cludes RCTs and nonrandomized studies and presents the evidence
and an assessment of its quality for important outcomes. The objective
was to assess the beneﬁts and harms of cryotherapy, LEEP, and CKC
for treatment of CIN. More speciﬁcally, the aim was to search for and
compare the beneﬁts and harms of the treatments (and also no treat-
ment) to inform decision makers who are faced with decisions about
how to treat CIN. When comparative studies were not available, non-
comparative studies were identiﬁed to assess the beneﬁts and harms.
Beneﬁts included a reduction in recurrence rates of CIN 2–3 in nonpreg-
nant women aged at least 18 years not previously treated for CIN; and
harms includedmajor andminor bleeding and infection, premature de-
livery, pelvic inﬂammatory disease (PID), HPV clearance, and damage to
other organs. Harms could be reported in nonpregnantwomenwith CIN
1–3 receiving treatment, because the harms would probably be similar
irrespective of CIN stage.
2. Materials and methods
Medline, Embase, the Cochrane Library, the Chinese Biomedicine Lit-
erature Database, the Chinese Scientiﬁc Journal Full-text Database, the
Chinese Journal Full-text Database, and the Wanfang Database were
searched up to February 2012 for beneﬁts, and up to July 2012 for
harms. The search strategy consisted of keywords speciﬁc to the data-
base and text words for the treatment options, CIN, and cervical cancer
(SupplementaryMaterial S1). The searchwas not restricted by language
or study design. The reference lists of relevant studies were also
reviewed and clinical experts in the specialty (e.g. members of the
WHO Guideline Development Group panel for the Recommendations
on Treatment and Screen and Treat Strategies for Cervical Cancer
Prevention [5]) contacted for additional references.
Two investigators independently screened titles, abstracts, and the
full text of relevant articles. A third investigator resolved disagreements.
Inclusion and exclusion criteria were deﬁned a priori. Studies had to in-
cludenonpregnantwomen aged 18 years or olderwhohadnot beenpre-
viously treated for CIN. RCTs and nonrandomized controlled trials
comparing women who received cryotherapy, LEEP, CKC, or no treat-
ment were included. Nonrandomized studies with one group were also
included but a minimum of 100 women had to receive cryotherapy,
LEEP, or CKC. Systematic reviews of these studies were also included.
For studies reporting beneﬁts, at least 90% of the participants had to
have histologically conﬁrmed CIN 2–3; for studies reporting harms, par-
ticipants could have been diagnosed with CIN 1–3. Studies had to report
data for at least one outcome identiﬁed by the WHO guideline panel as
important to decision making. The important outcomes were residual/
recurrent CIN 2–3 (at 12months), damage to other organs/other surgery
required (e.g. injury to bladder or urethra), major bleeding (requiring
hospitalization/blood transfusion), maternal death, HPV clearance
(after 6, 12, and 24 months), major infections (requiring hospitalization
and antibiotics), premature delivery, spontaneous abortions, PID, infer-
tility, and minor bleeding (requiring packing or suturing).
Two investigators independently collected data for patient character-
istics, diagnosis, treatments, setting, follow-up, and outcomes using a
pretested data abstraction form. The quality/risk of bias was assessed for
each outcome from the studies using the Cochrane risk of bias tool for
RCTs [6] and the domains of theNewcastle-Ottawa Scale for observational
studies [7]. Data were analyzed using RevMan 5.2 (The Nordic Cochrane
Center, Copenhagen, Denmark). Relative risks (e.g. risk ratios [RRs] and
odds ratios)were calculated bypooling results fromRCTs and fromobser-
vational studies comparing treatments. When no direct comparisons be-
tween treatments (e.g. cryotherapy vs CKC) within a study were
available, the risk of an event (or proportion) in a study (e.g. recurrence
of CIN 2–3 for cryotherapy) was calculated and then the proportions
from each study weighted by the generic inverse variance werecombined. The relative effect between two treatments was then calculat-
ed by dividing the overall proportion for one treatment (e.g. cryotherapy)
by the overall proportion for the other treatment (e.g. CKC). All results
were normalized to effects over a period of 1 year, with the exception of
adverse events, most of which would be likely to occur and be reported
within the ﬁrst year. Exploration of moderate to high heterogeneity
(I2 N 50%) and a subgroup analysis for HIV-positivewomenwere planned,
but identiﬁed data were inadequate.
Two investigators evaluated the quality of the evidence for each out-
come using the GRADE (Grading of Recommendations Assessment, De-
velopment and Evaluation) approach, and a third investigator helped to
resolve any discrepancies [8]. The quality of the evidence/conﬁdence in
the results of thepresent systematic reviewwere assessed as high,mod-
erate, low or very low. The effects and quality of evidencewere summa-
rized in GRADE Evidence tables for the WHO guideline update [5].
3. Results
3.1. Search results
Among 2703 nonduplicate records identiﬁed from the electronic da-
tabase search and from other sources, 611 articles in full text were re-
trieved after title and abstract screening (Fig. 1). After exclusion of
articles thatwere not relevant, 167 studieswere included. Theywere ei-
ther RCTs or nonrandomized studies (comparing two or more treat-
ments, or following one group receiving treatment).
3.2. Cryotherapy, LEEP, or CKC versus no treatment
None of the RCTs identiﬁed compared any of the three treatments
with no treatment. One nonrandomized study compared cryotherapy
with no treatment for prevention of CIN 2–3 recurrence [9] and one sys-
tematic review compared all treatments with no treatment for prema-
ture delivery [10]. All other outcomes were assessed by pooling
proportions from studies of one group receiving treatment.
Detailed results are shown in Table 1 and the study data are avail-
able in Supplementary Material S2. Brieﬂy, the recurrence rate of CIN
2–3 seems to be similar with cryotherapy or LEEP (~5%), but are
lower with CKC (~1%). However, there was high heterogeneity across
studies for each treatment (I2 = 84%–93%). Major and minor adverse
events seem to occur in less than 1% of women, with the exception of
minor bleeding when receiving CKC (affecting ~2.4%). Generally, there
were more adverse events with CKC than with LEEP, and more with
LEEP than with cryotherapy.
The systematic review of premature delivery (b37 weeks) [10]
found that the relative risk of premature delivery was greater with
any treatment than with no treatment. The highest risk of premature
birth was with CKC, and the lowest with LEEP. HPV clearance was not
measured in cryotherapy studies, but was assessed in one small study
of LEEP and one of CKC providing little data to make conclusions.
Maternal mortality was not measured. Infertility and spontaneous
abortions due to earlier treatment among nonpregnant women were
selectively measured and reported. The available data suggested that
there are few events with treatment (Table 2).
The quality of the evidence for all outcomeswas low to very low, be-
cause there were no randomized studies that compared the treatments
with no treatment. When data could be pooled, heterogeneity among
studies was high.
3.3. Comparisons between treatments
Few RCTs and nonrandomized studies were found that compared
one treatment with another treatment. When direct comparisons with-
in studies were available, relative risks and risk differences were calcu-
lated (Supplementary Material S3).
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Fig. 1. Flow diagram of study selection.
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with LEEP [25]. This RCT showed greater recurrence rates of CIN 2–3 at
12 months after cryotherapy, irrespective of HIV status (RR 3.00; 95%
conﬁdence interval [CI] 0.98–9.14). The opposite effect was shown in a
non-randomized study comparing the two treatments (RR 0.78; 95% CI
0.12–5.07) [26], although the conﬁdence intervals did include the poten-
tial for greater recurrence.
There were no episodes of major bleeding or major infections re-
ported in the RCT, but an indirect comparison between studies eval-
uating cryotherapy or LEEP showed that fewer major infections
(including PID) might occur with cryotherapy (RR 0.12; 95% CI
0.06–0.28). The RCT reported fewer minor bleeds in women receiv-
ing cryotherapy (RR 0.46; 95% CI 0.37–0.56).
An indirect comparison was conducted for premature delivery by
comparing the risks from the systematic review of studies comparing
LEEP with no treatment and cryotherapy with no treatment [10], and
showed that there could be a greater risk of premature birth with cryo-
therapy (RR 1.22; 95% CI 0.08–19.30). However, only one small study
contributed to the results for cryotherapy versus no treatment. There
were no direct comparisons for spontaneous abortions or infertility,
and no data to compare HPV clearance or maternal mortality.There was moderate-quality evidence for CIN 2–3 recurrence, and
major and minor bleeding after cryotherapy or LEEP because of impre-
cise results (few events and participants in the studies). Evidence for
other outcomeswas very low quality, primarily because effectswere es-
timated using indirect comparisons between studies which evaluated
only one treatment.
For cryotherapy versus CKC, no randomized controlled trials were
identiﬁed. Six nonrandomized studies comparing treatments [26–31]
showed a greater frequency of recurrence of CIN 2–3 amongwomen re-
ceiving cryotherapy than among those receiving CKC (RR 3.23; 95% CI
2.63–3.96). Indirect comparisons between up to 44 studies evaluating
harms for cryotherapy or CKC showed that there could be fewer
major bleeds requiring hospital admission or blood transfusion
(RR 0.15; 95% CI 0.10–0.20), fewer major infections (including PID; RR
0.17; 95% CI 0.07–0.43), fewer womenwith damage to other organs re-
quiring surgery (RR 0.11; 95% CI 0.03–0.38), and fewer minor bleeds
(RR 0.03; 95% CI 0.02–0.06) with cryotherapy than with CKC.
Indirect evidence from a systematic review of premature delivery
[10] also showed that there may be a lower risk of premature delivery
(b37 weeks) with cryotherapy than with CKC (RR 0.70; 95% CI
0.05–4.16). There were no studies that provided a direct comparison
Table 1
Effects of cryotherapy, LEEP, and cold knife conization at 12 months.a
Outcomes Percentage/RR (95% CI)b Number of studies Number of events/number of
participants
Cryotherapy
Recurrence of CIN 2–3 5.342 (3.879 to 6.805) 12 562/13 907
Major bleeding 0.034 (−0.030 to 0.098) 17 39/11 570
Major infection 0.014 (−0.038 to 0.065) 18 7/11 938
PID 0.006 (−0.48 to 0.060) 13 3/10 995
Damage to organs 0.022 (−0.056 to 0.100) 7 3/4974
Minor bleeding 0.006 (−0.051 to 0.064) 17 12/8757
Premature delivery 2.25 (0.14 to 34.98)c 1 2/117
HPV clearance – – –
LEEP
Recurrence of CIN 2–3 5.312 (3.702 to 6.922) 19 391/8269
Major bleeding 0.226 (0.131 to 0.320) 40 121/16 423
Major infection 0.128 (0.011 to 0.245) 19 37/7796
PID 0.139 (0.005 to 0.273) 12 33/5913
Damage to organs 0.221 (0.070 to 0.371) 12 21/5727
Minor bleeding 0.363 (0.281 to 0.444) 53 308/19 861
Premature delivery 1.85 (1.59 to 2.15)c 8 26 352/656 581
HPV clearance 64.706 (56.242 to 73.169) 1 77/119
Cold knife conization
Recurrence of CIN 2–3 1.431 (0.8323 to 2.030) 11 228/17 616
Major bleeding 0.859 (0.651 to 1.066) 26 216/9311
Major infection 0.089 (−0.082 to 0.260) 11 12/3443
PID 0.138 (−0.032 to 0.309) 6 9/3003
Damage to organs 0.276 (0.057 to 0.494) 8 17/3180
Minor bleeding 2.450 (2.084 to 2.816) 27 324/7638
Premature delivery 3.41 (2.38 to 4.88)c 3 2009/30 216
HPV clearance 72.269 (64.322 to 80.216) 1 86/119
Abbreviations: LEEP, loop electrosurgical excision procedure including large loop excision of the transformation zone; RR, risk ratio; CIN, cervical intraepithelial neoplasia; PID, pelvic
inﬂammatory disease.
a On the basis of evidence of low to very low quality.
b Percentage unless otherwise indicated.
c RR.
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neous abortions. One nonrandomized study [30] reported that no deaths
occurred in mothers at childbirth with either treatment.
The quality of the evidence was low for recurrence of CIN 2–3 after
cryotherapy or CKC because of a lack of randomization in studies;
and very low for other outcomes as a result of imprecise results and
indirect comparisons.
For CKC versus LEEP, there were four RCTs [21,32–34]. Recurrence
rates of CIN 2–3 at 12months seemed to be lower with CKC thanwith
LEEP on the basis of two RCTs [32,33] (RR 0.53; 95% CI 0.14–1.98),
and also on the basis of data from seven nonrandomized studies
[23,26,31,35–38] (RR 0.66; 95% CI 0.36–1.20).
Three RCTs [21,32,38] showed a probable reduction of major bleeds
with CKC (RR 0.79; 95% CI 0.24–2.60). However, pooled results from
two non-randomized studies comparing the two treatments [39,40]
showed an RR of 3.42 (95% CI 0.14–50.49). Two RCTs [32,33] showed
a probable reduction in minor bleeds with CKC (RR 0.89; 95% CI
0.39–2.01), but data from three nonrandomized studies [23,40,41]
showed that minor bleeds could be increased with CKC (RR 3.91; 95%
CI 1.02–15.04). The risk of major infection (including PID) wasTable 2
Narrative summary of results for reproductive and fertility outcomes.
Outcome Cryotherapy LEEP
Infertility 4 nonrandomized studies reported 65/439 women
with infertility [11–14]
1 non-randomized s
no difference in time
compared with no t
Spontaneous
abortions
7 nonrandomized studies reported 12 spontaneous
abortions in 210 pregnancies with a range of 0%–15%
(follow-up 6 months to 10 years) [11–14,18–20]
3 nonrandomized s
12 spontaneous ab
Abbreviations: LEEP, loop electrosurgical excision procedure; CKC, cold knife conization.increased with CKC in one nonrandomized study [40] (RR 2.34; 95% CI
0.13–43.18). In an indirect comparison of 20 studies evaluating CKC or
LEEP, the risk of damage to other organs requiring surgery was in-
creased with CKC (RR 1.46; 95% CI 0.77–2.76).
There were two non-randomized studies comparing premature
delivery after CKC and LEEP [22,42]. The risk was increased with
CKC (RR 1.31; 95% CI 0.55–3.12). One RCT [21] measured spontane-
ous abortion and found that there were fewer with CKC than with
LEEP (RR 0.73; 95% CI 0.35–1.51). There were no direct comparisons
for infertility or HPV clearance.
There wasmoderate-quality evidence for major and minor bleeding
after CKC and LEEP because of imprecise results. The evidence for other
outcomes was of low to very low quality as a result of imprecise results
and indirect comparisons.
4. Discussion
The present systematic review of the literature was conducted to in-
formdecisionmaking about effective and safe treatments for CIN2–3. Un-
fortunately, althoughnot unexpectedly, only a few small RCTswere foundCKC
tudy of 134 women reported
to conceive at ≥3 years when
reatment [15]
1 nonrandomized study found no difference in time
to conceive in 36 women ≤24 months [16]; another
found no infertility ≤12 months in 166 women [17]
tudies of 207 women reported
ortions [21–23]
3 nonrandomized studies found 10 spontaneous
abortions in 1090 women [22–24]
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to decision making. Thus, to ﬁll the gaps in the evidence, the search also
included nonrandomized studies. Most of those reported results of one
group of women who received one type of treatment. Therefore, these
data were pooled together to determine the proportion of women who
experience beneﬁts and harms when provided with the treatments.
Moderate-quality evidence comparing cryotherapy with LEEP was
found for some outcomes. This evidence suggests that recurrence of
CIN 2–3 is probably reduced with LEEP, although there are probably
fewer or similar rates of major and minor complications with cryother-
apy. Low- to very-low-quality evidence was identiﬁed from indirect
comparisons between LEEP and no treatment, and cryotherapy and no
treatment; the data suggested that there are few differences in
reproductive-related outcomes.
Moderate- to low-quality evidence was identiﬁed for the compari-
son of CKCwith LEEP for some outcomes. Recurrence of CIN 2–3 is prob-
ably reducedwith CKC, as ismajor andminor bleeding. One explanation
for the reduction in bleeding is that conditions could be better con-
trolled during CKC surgical procedures. However, for other complica-
tions, low- to very-low-quality evidence was found from indirect
comparisons between LEEP and no treatment, and between CKC and
no treatment, that suggests that major infections, damage to other or-
gans requiring surgery, and premature delivery could be increased
with CKC when compared with LEEP.
Not surprisingly, evidence from indirect comparisons between cryo-
therapy and CKC suggested that recurrence of CIN 2–3 could be greater
with cryotherapy but there are fewer complications with cryotherapy
than with CKC. The evidence was of low to very low quality.
Overall, insufﬁcient data were identiﬁed to draw conclusions about
outcomes that have been identiﬁed as critical when making decisions
about treating CIN 2–3 to prevent cervical cancer. There was very-
low-quality evidence and often no evidence at all from studies for re-
productive outcomes, such as infertility, spontaneous abortions, and
maternalmortality. However, the evidence does suggest that premature
delivery could be increasedwith treatment, which could be a concern to
women undergoing treatment and their partners.
The present review has many strengths and some limitations. Cur-
rent reviews of the literature have restricted the search to randomized
controlled trials that can potentially provide the highest quality of evi-
dence. Given the dearth of RCTs in the area, the present search included
nonrandomized controlled trials. The search was systematic and com-
prehensive, and consisted of searches in multiple electronic databases
and requests to experts in the ﬁeld.When searching, a plethora of stud-
ies following one group of women who received one intervention were
identiﬁed, somewith fewer than100participants. The present study ex-
cluded these nonrandomized studies with fewer than 100 women; al-
though this cutoff was arbitrary, it was felt that studies with larger
groups of women would have more rigorous design methods to follow
up participants and measure outcomes. Despite this restriction, most
outcomes included between 3000 and 20 000 women. Additionally,
the review did not rely solely on direct comparisons. Instead, risk differ-
ences and relative risks were calculated for outcomes between studies
in which women received one intervention and studies in which
women received another intervention. Although these indirect compar-
isons provide a lower quality of evidence because of the potential for se-
lection bias, it was felt that low- or very-low-quality evidence would be
more informative to decision makers than would no evidence.
In conclusion, the present reviewprovides a summary of the beneﬁts
and harms of cryotherapy, LEEP, and CKC to treat CIN among nonpreg-
nantwomen to prevent progression to cervical cancer. This information
has been used to inform the development of WHO recommendations
for the treatment of CIN 2–3 to prevent cervical cancer. The beneﬁts
and harms of the treatments found in the present review can be consid-
ered along with the values and preferences of patients, resources, and
feasibility issues to decide which treatment to provide. The data were
also used to inform recommendations about screen-and-treat strategiesto prevent cervical cancer. It is hoped that additional research into the
outcomes important to decision makers will be done to ﬁll the gaps
identiﬁed in the current literature.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijgo.2015.07.026.
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